



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/SG/2024-25/150

January 07, 2025

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <b>Scrip Code - 532523</b>	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 <b>Scrip Symbol - Biocon</b>
--	---

Dear Sir/Madam,

**Subject: Notification to Stock Exchanges**

Please find enclosed the company statement titled “**Japan Health Authority (PMDA) Approves Biocon Biologics’ Ustekinumab BS, Biosimilar to J&J's Stelara®**”.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

\_\_\_\_\_  
**Mayank Verma**  
**Company Secretary & Compliance Officer**  
**Membership No: ACS 18776**

Encl: as above

**NOTIFICATION TO STOCK EXCHANGE**

**COMPANY STATEMENT**

**Japan Health Authority (PMDA) Approves Biocon Biologics'  
Ustekinumab BS, Biosimilar to J&J's Stelara®**

***Bengaluru, Karnataka, India, January 07, 2025***

**Biocon Biologics Ltd (BBL)**, a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that **the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan has approved** Ustekinumab BS subcutaneous injection [YD], **a biosimilar to** the reference product, Stelara® (*Ustekinumab*). The biosimilar Ustekinumab has been developed and manufactured by the Company and will be commercialized and marketed in Japan by the Company's exclusive commercial partner, Yoshindo Inc.

**Ustekinumab, a monoclonal antibody, is approved for the treatment of Psoriasis Vulgaris and Psoriatic Arthritis (PsA).**

**Biocon Biologics Ltd previously notified** the Stock Exchange on Aug 29, 2024, that the Company had entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) **to commercialize Ustekinumab in Japan, upon regulatory approval.**

*– Company Spokesperson*

*For more information: [seema.ahuja@biocon.com](mailto:seema.ahuja@biocon.com)*